PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

NMBAs in Ventilated Sepsis: No Mortality Signal, Longer ICU Stay, More VAP

neuromuscular blocking agentscisatracuriumvecuroniumrocuroniumsepsismechanical ventilationventilator-associated pneumoniapropensity score matchinginverse probability of treatment weightingICU length of stayobservational cohortcritical care Critical Care / ICU

Background Information

NMBA use in sepsis raises ICU stay and pneumonia risk.

The impact of neuromuscular blocking agents (NMBAs) on outcomes in septic patients needing mechanical ventilation is unclear and impacts ICU management strategies. NMBA use did not affect in-hospital mortality but led to longer ICU stays (3 days longer) and increased ventilator-associated pneumonia (8.6% vs. 4.5%). The study highlights potential risks of NMBA use in sepsis patients, including longer ICU stays, suggesting cautious use in practice. NMBA use in sepsis increases ICU stay and pneumonia risk without mortality benefit.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Nam H, Lim SY, Lee KJ, Lee YJ, Ko RE, Suh GY, Cho WH, Hyun DG, Lim CM, Park S, Korean Sepsis Alliance (KSA) Investigators

Citation: Nam H, Lim SY, Lee KJ, et al. Impact of Neuromuscular Blocking Agents on Hospital Outcomes in Mechanically Ventilated Patients With Sepsis: Propensity Score Analyses of A Nationwide Sepsis Cohort. Journal of Korean medical science. 2026;41(42):e284. doi:10.3346/jkms.2026.41.e284

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.